CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson’s disease
2020 · Nature Communications · 74 citations
https://doi.org/10.1038/s41467-020-18689-x
E
Emilie Faggiani
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
24
Papers
462
Citations
10
h-index
10
i10-index
Emilie Faggiani is an academic researcher from Trevi Therapeutics (United States). The author has contributed to research in topics: Parkinson's Disease Mechanisms and Treatments & Neurological disorders and treatments & Neuroscience and Neural Engineering. The author has an h-index of 10, co-authored 21 publications.
ORCID: 0000-0002-9872-9232Papers by this author
worksSerotonergic neurons mediate the anxiolytic effect of l-DOPA: Neuronal correlates in the amygdala
2017 · Neurobiology of Disease · 16 citations
https://doi.org/10.1016/j.nbd.2017.11.001
Bioreactor-produced iPSCs-derived dopaminergic neuron-containing neural microtissues innervate and normalize rotational bias in a dose-dependent manner in a Parkinson rat model
2024 · Neurotherapeutics · 4 citations
https://doi.org/10.1016/j.neurot.2024.e00436
DEVELOPMENT OF A DELIVERY STRATEGY FOR NEURAL MICROTISSUES IN PARKINSON'S DISEASE CELL THERAPY
2025 · Cytotherapy · 0 citations
https://doi.org/10.1016/j.jcyt.2025.03.464
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat